Emergent BioSolutions (EBS) Revenue (2011 - 2026)

Emergent BioSolutions' Revenue history runs 16 years deep, the most recent figure standing at $156.1 million for Q1 2026.

• On a quarterly basis, Revenue fell 29.75% year-over-year to $156.1 million in Q1 2026; TTM through Mar 2026 was $676.8 million, a 11.03% decrease from a year earlier, with the FY2025 full-year figure at $742.9 million, down 28.81% from the prior year.
• Revenue climbed to $156.1 million in Q1 2026 per EBS's latest filing, from $148.7 million in the prior quarter.
• Across five years, Revenue topped out at $337.9 million in Q2 2023 and bottomed at $50.0 million in Q2 2024.
• The 5-year median for Revenue is $239.9 million (2022), against an average of $229.7 million.
• Across the five-year window, Revenue sank 85.2% in 2024 and soared 181.8% in 2025, its largest moves.
• Year by year, Revenue stood at $330.2 million in 2022, then decreased by 16.23% to $276.6 million in 2023, then slipped by 29.61% to $194.7 million in 2024, then retreated by 23.63% to $148.7 million in 2025, then increased by 4.98% to $156.1 million in 2026.
• Per Business Quant, the three latest EBS Revenue figures stand at $156.1 million (Q1 2026), $148.7 million (Q4 2025), and $231.1 million (Q3 2025).